EnVVeno Medical Corporation’s VenoValve, a one-way circulatory valve, was associated with a 54 percent improvement in backward blood flow prevention and a 76 percent improvement in pain, the company said March 9. It is designed to help restore proper directional blood flow up the leg to return sufficient blood back to the heart.
“The current standard of care for deep venous [chronic venous insufficiency]has significant shortcomings, and we believe the VenoValve could be the effective solution that frustrated doctors and their patients have been seeking for decades,” EnVVeno CEO Robert Berman said.
The FDA has granted VenoValve with its breakthrough device designation, EnVVeno said.
The trial was a non-randomized study with 11 patients in a single center.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
